Core Viewpoint - The announcement details the completion of additional share pledges by the controlling shareholder of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., aimed at securing a bond issuance, with significant implications for the company's financial stability and shareholder structure [1][2]. Group 1: Share Pledge Details - As of February 5, 2026, the controlling shareholder, Heilongjiang Chuangda Group Co., Ltd., holds 523,231,148 shares, representing 55.60% of the total share capital, with 421,115,848 shares pledged, accounting for 80.48% of its holdings [2][4]. - The controlling shareholder has pledged an additional 1,170,000 shares to secure the 23 Chuang 02EB bond, with the pledge completed on February 6, 2026 [3][4]. - The total number of pledged shares has decreased due to a bond conversion, with the previous pledge count adjusted accordingly [4]. Group 2: Financial Health and Risk Assessment - The controlling shareholder has no significant litigation or arbitration issues related to debt, and its operational and performance status is normal, with debt repayment sources identified [9][10]. - The controlling shareholder's total outstanding exchangeable bonds amount to 427.25 million yuan, with no immediate repayment risks identified [9]. - The company assesses that the current pledge situation does not pose a risk of forced liquidation or transfer, and the controlling shareholder is expected to take proactive measures if necessary [10].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603757 证券简称：大元泵业 公告编号：2026-002 浙江大元泵业股份有限公司关于公司控股股东拟协议转让部分股份的预披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 韩元再、韩元平、韩元富、王国良、徐伟建构成一致行动关系，为浙江大元泵业股份公司（以下简 称"公司"）的控股股东及实际控制人。截至本公告日，上述五位股东均持有21,089,600股公司股份，占 公司总股本的比例均为11.31%；合计持有105,448,000股公司股份，占公司总股本的比例为56.53%。 韩元再、徐伟建计划自本公告披露之日起3个交易日后的3个月内拟通过协议转让的方式合计转让其持有 的公司股份不高于9,405,000股,不高于公司总股本的 5.05%，届时将另行披露相关公告和权益变动报告 书。 ● 本次协议转让不会导致公司控股股东及实际控制人发生变化，不涉及要约收购，亦不会对公司未来持 续经营产生重大影响。 公司于近日收到韩元再、徐伟建的通知，其拟将持 ...

Core Viewpoint - The company reported its preliminary financial data for the year 2025, indicating stable revenue and significant growth in net profit, driven by the expanding domestic and global electric vehicle market. Financial Performance - In 2025, the company achieved total operating revenue of 634,176.87 million RMB, remaining stable compared to the previous year - The net profit attributable to the parent company was 55,712.93 million RMB, representing a year-on-year increase of 39.22% - The net profit attributable to the parent company after deducting non-recurring gains and losses was 52,149.69 million RMB, with a year-on-year growth of 46.71% [1][2] Financial Position - As of the end of 2025, the company's total assets amounted to 822,603.24 million RMB, reflecting a year-on-year growth of 6.96% - The equity attributable to the parent company reached 362,611.22 million RMB, which is a 10.89% increase compared to the previous year [2] Key Growth Drivers - The increase in operating profit, net profit, and earnings per share exceeding 30% is attributed to: 1. Steady growth in domestic electric vehicle sales and penetration rates, leading to increased shipment volume and revenue from the company's power supply products 2. The company's focus on lean production management and increased R&D investment, resulting in an improved product mix with a higher proportion of high-value-added products [3]

昆山东威科技股份有限公司2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 证券代码：688700 证券简称：东威科技 公告编号：2026-004 公司2025年度实现营业总收入110,738.57万元，同比增长47.65%；实现归属于母公司所有者的净利润 12,940.71万元，同比增长86.81%；实现归属于母公司所有者的扣除非经常性损益的净利润12,508.36万 元，同比增长103.52%。 2、财务状况 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以昆山东威科技 股份有限公司（以下简称"公司"）2025年年度报告为准，提请投资者注意投资风险。 一、2025年年度主要财务数据和指标 单位：人民币万元 ■ 注：1.本报告期初数同法定披露的上年年末数。 2.以上财务数据及指标以合并报表数据填列，但未经审计，最终结果以公司2025年年度报告为准。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况、财务状况及影响经营业绩的主要因素 1、经营情况 2025年末， ...

Core Viewpoint - Chengdu Yuandong Biopharmaceutical Co., Ltd. has announced the completion of the first dosing of the EP-0210 monoclonal antibody injection in a Phase I clinical trial for treating inflammatory bowel disease, indicating progress in its drug development pipeline [1][3]. Group 1: Drug Overview - EP-0210 monoclonal antibody injection is a humanized IgG1 monoclonal antibody targeting TNF-like ligand 1A (TL1A), aimed at treating inflammatory bowel disease by blocking TL1A-mediated pro-inflammatory signaling pathways [1][2]. - Preclinical studies have shown that EP-0210 has a clear mechanism of action and significant efficacy in various inflammatory bowel disease models, demonstrating better target activity and efficacy compared to the foreign competitor RVT-3101 [2]. Group 2: Clinical Trial Details - The Phase I clinical trial for EP-0210 received formal approval from the National Medical Products Administration in January 2026, with the trial focusing on safety, tolerability, pharmacokinetics, and immunogenicity in healthy adult participants [3]. - As of the announcement date, the first dosing in the single-dose administration phase of the trial has been completed [3].

Core Viewpoint - Ningbo Meinuo Pharmaceutical Co., Ltd. plans to repurchase and cancel a total of 181,100 restricted stocks due to the departure of 17 incentive targets from the 2024 stock incentive plan, in accordance with the relevant provisions of the plan and the authorization from the 2023 annual general meeting [2][3]. Group 1: Repurchase and Cancellation Details - The decision for the repurchase and cancellation of restricted stocks was approved at the 21st meeting of the fifth board of directors held on December 15, 2025 [3]. - The repurchase price is set at 6.52 yuan per share, totaling 1,180,772 yuan for the repurchase [3]. - The repurchase funds will be sourced from the company's own funds [4]. Group 2: Legal and Regulatory Compliance - The company has fulfilled its obligation to notify creditors regarding the reduction of registered capital due to the repurchase and cancellation of shares [4]. - No creditors raised objections or requested debt repayment within the stipulated time frame [4]. - The company has confirmed that the decision-making process and information disclosure comply with relevant laws and regulations [8]. Group 3: Impact on Share Structure - Following the repurchase and cancellation, the total number of shares will decrease from 220,631,264 to 220,450,164 [7]. - The registered capital will also be reduced from 220,631,264 yuan to 220,450,164 yuan [7]. - After the cancellation, the remaining restricted stocks held by the involved personnel will be zero, while the company will have 4,254,280 shares of restricted stocks remaining [6].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：001233 证券简称：海安集团公告编号：2026-004 海安橡胶集团股份公司 第二届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 海安橡胶集团股份公司（以下简称"公司"）第二届董事会第十九次会议于2026年2月9日在公司会议室以 现场结合通讯方式召开，会议通知于2026年2月4日以专人送出方式送达给全体董事和高级管理人员。本 次会议应出席董事9人，实际出席会议董事9人（其中朱剑水先生、何明轩女士、吴任华女士、李楠女 士、陆雅女士、温廷羲先生以通讯方式出席）。本次会议由公司董事长朱晖先生召集并主持，全体高级 管理人员列席了本次会议。本次会议的召集、召开符合《中华人民共和国公司法》和《海安橡胶集团股 份公司章程》的有关规定。 二、董事会会议审议情况 （一）审议通过了《关于对外投资设立香港全资子公司的议案》 表决结果为：9票赞成，0票反对，0票弃权。 本议案经公司战略委员会审议通过。 具体内容详见同日刊登于巨潮资讯网（www.cninfo.com.c ...

第十届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 万方城镇投资发展股份有限公司（以下简称"公司"）第十届董事会第八次会议通知于2026年2月6日以通 讯形式发出，会议于2026年2月9日下午14:30时在北京市朝阳区裕民路12号中国国际科技会展中心B座 12A公司会议室以通讯的方式召开，会议应到董事9名，实到9名，会议由董事长刘玉女士主持，本次会 议召开符合《公司法》及《公司章程》的相关规定。会议审议并通过了如下议案： 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000638 证券简称：*ST万方 公告编号：2026-021 万方城镇投资发展股份有限公司 二、以9票同意，0票反对，0票弃权，审议通过了《关于召开2026年第一次临时股东会的议案》。 内容详见公司于本公告同日在《中国证券报》《证券时报》《上海证券报》《证券日报》及巨潮资讯网 （http://www.cninfo.com.cn）上披露的《关于召开2026年第一次临时股东会的公告》（公告编号：2026- 023）。 特此公告。 万方城镇投资发展股份有限公司 ...

Summary of Key Points Core Viewpoint The announcement details the resolutions passed during the first extraordinary general meeting of shareholders for Inner Mongolia Shuangxin Environmental Protection Materials Co., Ltd. in 2026, highlighting the approval of various proposals related to corporate governance and capital structure. Group 1: Meeting Details - The meeting was held on February 9, 2026, at 14:30, combining on-site voting and online voting [1][2] - A total of 859 shareholders and authorized representatives attended, representing 863,433,671 shares, which is 75.2776% of the total voting shares [3] - The meeting was convened and conducted in accordance with the Company Law and the Articles of Association [2][5] Group 2: Voting Results - All proposals presented at the meeting were approved without any rejections [5][7] - Proposal 1 regarding changes to registered capital and company type received 99.8973% approval from the voting shares [8] - Proposal 2 concerning the revision of governance rules also passed with 99.8950% approval [11] Group 3: Specific Proposals - Proposal 1 included changes to the registered capital and company type, which was a special resolution requiring over two-thirds approval [7] - Proposal 4, which involved anticipated related party transactions for 2026, was approved with 99.7096% support from non-related shareholders [50] - Proposal 6 regarding the appointment of the auditing firm for 2025 was also passed with 99.8943% approval [55] Group 4: Legal Compliance - The meeting was witnessed by lawyers from Beijing Deheng Law Firm, confirming that the meeting's procedures and resolutions complied with relevant laws and regulations [57]

Core Viewpoint - Shanghai is enhancing its cultural and tourism offerings during the upcoming Spring Festival, with a total of 2,570 activities planned to attract residents and tourists to celebrate the New Year in the city [4][8]. Group 1: Cultural and Tourism Activities - The Shanghai Cultural and Tourism Bureau has announced 2,570 activities across seven categories, including festive events, performances, museum exhibitions, and intangible cultural heritage activities [4][8]. - Major tourist attractions in Pudong will feature unique New Year activities, such as Shanghai Disneyland's "Winter Wonderland" and the Shanghai Ocean Aquarium's whale greeting event [7]. - The Shanghai Art Museum will showcase 105 masterpieces from renowned artists, providing free access to the public [8]. Group 2: Business Initiatives - Yao Xue Ice and Snow World has reported a 70% increase in overall visitor numbers and a 40% rise in revenue year-on-year since the beginning of 2026, with expectations of a 20% increase in visitor numbers during the Spring Festival [5][6]. - Jin Jiang International Group is promoting nearly 100 Shanghai-themed tourism products, focusing on immersive experiences and deep engagement with the city [9]. - Yu Garden Holdings is integrating traditional lantern displays with modern technology and art to create a comprehensive Spring Festival experience that combines sightseeing, interaction, and consumption [9].